Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Combination Anti-CTLA-4 and Anti-RANKL in Metastatic Melanoma.

× No keyword cloud information.

25 in total

Review 1. Role of RANKL in cancer development and metastasis.

Authors: Kazuo Okamoto
Journal: J Bone Miner Metab Date: 2021-01-02 Impact factor: 2.626

Review 2. Discovery of the RANKL/RANK/OPG system.

Authors: Hisataka Yasuda
Journal: J Bone Miner Metab Date: 2021-01-03 Impact factor: 2.626

Review 3. Pulling RANK on Cancer: Blocking Aire-Mediated Central Tolerance to Enhance Immunotherapy.

Authors: Maureen A Su; Mark S Anderson
Journal: Cancer Immunol Res Date: 2019-06 Impact factor: 11.151

4. An observational study of concomitant immunotherapies and denosumab in patients with advanced melanoma or lung cancer.

Authors: Alexander Liede; Rohini K Hernandez; Sally W Wade; Ronghai Bo; Nathan C Nussbaum; Elizabeth Ahern; William C Dougall; Mark J Smyth
Journal: Oncoimmunology Date: 2018-09-05 Impact factor: 8.110

5. Combination central tolerance and peripheral checkpoint blockade unleashes antimelanoma immunity.

Authors: Pearl Bakhru; Meng-Lei Zhu; Hsing-Hui Wang; Lee K Hong; Imran Khan; Maria Mouchess; Ajay S Gulati; Joshua Starmer; Yafei Hou; David Sailer; Sandra Lee; Fengmin Zhao; John M Kirkwood; Stergios Moschos; Lawrence Fong; Mark S Anderson; Maureen A Su
Journal: JCI Insight Date: 2017-09-21

Review 6. RANKL biology.

Authors: Noriko Takegahara; Hyunsoo Kim; Yongwon Choi
Journal: Bone Date: 2022-02-16 Impact factor: 4.626

7. RANKL-Targeted Combination Therapy with Osteoprotegerin Variant Devoid of TRAIL Binding Exerts Biphasic Effects on Skeletal Remodeling and Antitumor Immunity.

Authors: Hong Wang; Reading Ashton; Jonathan A Hensel; Joo Hyoung Lee; Vinayak Khattar; Yong Wang; Jessy S Deshane; Selvarangan Ponnazhagan
Journal: Mol Cancer Ther Date: 2020-11-16 Impact factor: 6.261

8. RANK expression in EBV positive nasopharyngeal carcinoma metastasis: a ready-to-treat target?

Authors: Carlo Resteghini; Salvatore Alfieri; Pasquale Quattrone; Francesca Dominoni; Giovanna Garzone; Ester Orlandi; Laura Locati; Cristiana Bergamini; Donata Galbiati; Nicola Alessandro Iacovelli; Carlo Fallai; Lisa Licitra; Paolo Bossi
Journal: Oncotarget Date: 2017-10-16

9. Tumor microenvironment in giant cell tumor of bone: evaluation of PD-L1 expression and SIRPα infiltration after denosumab treatment.

Authors: Yu Toda; Kenichi Kohashi; Hidetaka Yamamoto; Shin Ishihara; Yoshihiro Ito; Yosuke Susuki; Kengo Kawaguchi; Daisuke Kiyozawa; Dai Takamatsu; Izumi Kinoshita; Yuichi Yamada; Junki Maehara; Atsushi Kimura; Sadafumi Tamiya; Kenichi Taguchi; Tomoya Matsunobu; Yoshihiro Matsumoto; Yasuharu Nakashima; Masaaki Mawatari; Yoshinao Oda
Journal: Sci Rep Date: 2021-07-20 Impact factor: 4.379

10. Complications of bone metastases from malignant melanoma.

Authors: Jamal Zekri; Maria Marples; Dominic Taylor; Kiran Kandukurti; Lucy McParland; Janet E Brown
Journal: J Bone Oncol Date: 2017-08-18 Impact factor: 4.072